SREBF1 and cancer: Similarly, oncogenic mutations activating the PI3K–AKT–mTORC1 pathway (e.g., PIK3CA mutations, PTEN deletions) confer ferroptosis resistance in cancer cells by upregulating SREBP1 and its downstream effector, SCD1 [61].